1. Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates.
- Author
-
Mazzarello, Andrea N., Gugiatti, Elena, Cossu, Vanessa, Bertola, Nadia, Bagnara, Davide, Carta, Sonia, Ravera, Silvia, Salvetti, Chiara, Ibatici, Adalberto, Ghiotto, Fabio, Colombo, Monica, Cutrona, Giovanna, Marini, Cecilia, Sambuceti, Gianmario, Fais, Franco, and Bruno, Silvia
- Subjects
CHRONIC lymphocytic leukemia ,B cells ,CHRONIC leukemia ,DIPHOSPHONATES ,STROMAL cells ,CYTOTOXINS - Abstract
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, often presenting comorbidities like osteoporosis and requiring, in a relevant proportion of cases, treatment with bisphosphonates (BPs). This class of drugs was shown in preclinical investigations to also possess anticancer properties. We started an in vitro study of the effects of BPs on CLL B cells activated by microenvironment-mimicking stimuli and observed that, depending on drug concentration, hormetic effects were induced on the leukemic cells. Higher doses induced cytotoxicity whereas at lower concentrations, more likely occurring in vivo, the drugs generated a protective effect from spontaneous and chemotherapy-induced apoptosis, and augmented CLL B cell activation/proliferation. This CLL-activation effect promoted by the BPs was associated with markers of poor CLL prognosis and required the presence of bystander stromal cells. Functional experiments suggested that this phenomenon involves the release of soluble factors and is increased by cellular contact between stroma and CLL B cells. Since CLL patients often present comorbidities such as osteoporosis and considering the diverse outcomes in both CLL disease progression and CLL response to treatment among patients, illustrating this phenomenon holds potential significance in driving additional investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF